PMUC1CALLO-1 is a gene-modified cell therapy commercialized by Poseida Therapeutics, with a leading Phase I program in Triple-Negative Breast Cancer (TNBC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of PMUC1CALLO-1’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for PMUC1CALLO-1 is expected to reach an annual total of $7 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
P-MUC1CALLO-1 is under development for the treatment of solid tumors derived from epithelial cells tumors including triple-negative breast cancer, renal cancer, ovarian cancer, non-small cell lung cancer, esophageal cancer, gastric cancer, pancreatic cancer and colorectal cancers. It comprises of allogeneic stem memory T cells (Tscm), genetically engineered to express chimeric antigen receptor (CAR). It acts by targeting the cells expressing mucin1. The therapeutic candidate is being developed based on Piggybac DNA modification system and CAS Clover gene-editing technology.
Poseida Therapeutics Overview
Poseida Therapeutics is a biopharmaceutical company. It harnesses its proprietary gene engineering platform, to develop next generation cell and gene therapeutics to treat solid tumors and hematological malignancies. The company is investigating its lead product candidate P-BCMA-101, an autologous CAR-T therapy against refractory multiple myeloma. It is also evaluating P-PSMA-101 and P-PSMA-ALL01, allogeneic chimeric antigen receptors for the treatment of prostate cancer; and Dual car (CD19/CD20) targeting solid tumor. Poseida Therapeutics is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$31.2 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$121.9 million in FY2021, compared to an operating loss of US$126.6 million in FY2020. The net loss of the company was US$125 million in FY2021, compared to a net loss of US$129.8 million in FY2020. The company reported revenues of US$116.3 million for the third quarter ended September 2022, compared to a revenue of US$2.7 million the previous quarter.
For a complete picture of PMUC1CALLO-1’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.